Page 114 - Read Online

Page 10 of 11 Gawel et al. J Cancer Metastasis Treat 2022;8:26 https://dx.doi.org/10.20517/2394-4722.2022.13

21. Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening - a perspective on the current state of the evidence. N Engl J Med
2017;376:1285-9. DOI PubMed
22. Kleif J, Ferm L, Davis GJ, Christensen IJ, Nielsen HJ. 898 Development of blood-based, cancer-associated biomarkers for early
detection of colorectal cancer: significant differences between results from symptomatic and screening subjects. Gastroenterology
2020;158:S-1538. DOI
23. Wen YH, Chang PY, Hsu CM, Wang HY, Chiu CT, Lu JJ. Cancer screening through a multi-analyte serum biomarker panel during
health check-up examinations: results from a 12-year experience. Clin Chim Acta 2015;450:273-6. DOI PubMed
24. Chung S. False-positive elevations in carcinoembryonic antigen levels at a health screening center. Lab Med Online 2019;9:146. DOI
25. Wang HY, Hsieh CH, Wen CN, Wen YH, Chen CH, Lu JJ. Cancers Screening in an Asymptomatic Population by Using Multiple
Tumour Markers. PLoS One 2016;11:e0158285. DOI PubMed PMC
26. Wang HY, Chen CH, Shi S, et al. Improving multi-tumor biomarker health check-up tests with machine learning algorithms. Cancers
(Basel) 2020;12:1442. DOI PubMed PMC
27. National Cancer Institute. Tumor markers in common use. Available from: https://www.cancer.gov/about-cancer/diagnosis-
staging/diagnosis/tumor-markers-list [Last accessed on 29 June 2022].
28. Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating
tumor DNA. Tumour Biol 2018;40:1010428318776169. DOI PubMed
29. Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol
2019;14:343-57. DOI PubMed PMC
30. Cargnin S, Canonico PL, Genazzani AA, Terrazzino S. Quantitative analysis of circulating cell-free DNA for correlation with lung
cancer survival: a systematic review and meta-analysis. J Thorac Oncol 2017;12:43-53. DOI PubMed
31. Qvick A, Stenmark B, Carlsson J, Isaksson J, Karlsson C, Helenius G. Liquid biopsy as an option for predictive testing and prognosis
in patients with lung cancer. Mol Med 2021;27:68. DOI PubMed PMC
32. Tissot C, Toffart AC, Villar S, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur
Respir J 2015;46:1773-80. DOI PubMed
33. González de Aledo-Castillo JM, Casanueva-Eliceiry S, Soler-Perromat A, et al. Cell-free DNA concentration and fragment size
fraction correlate with FDG PET/CT-derived parameters in NSCLC patients. Eur J Nucl Med Mol Imaging 2021;48:3631-42. DOI
PubMed
34. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating
tumor DNA profiling. Cancer Discov 2017;7:1394-403. DOI PubMed PMC
35. Phallen J, Leal A, Woodward BD, et al. Early noninvasive detection of response to targeted therapy in non-small cell lung cancer.
Cancer Res 2019;79:1204-13. DOI PubMed PMC
36. Sestini S, Boeri M, Marchiano A, et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed
tomography screening. Oncotarget 2015;6:32868-77. DOI PubMed PMC
37. Liu MC. Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future
prospects. Br J Cancer 2021;124:1475-7. DOI PubMed PMC
38. Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin
Chem Lab Med 2021;59:1353-61. DOI PubMed
39. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide
intervention. Science 2020;369:eabb9601. DOI PubMed PMC
40. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in
cell-free DNA. Ann Oncol 2020;31:745-59. DOI PubMed PMC
41. Wan N, Weinberg D, Liu TY, et al. Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing
of plasma cell-free DNA. BMC Cancer 2019;19:832. DOI PubMed PMC
42. Lin J, Ariazi E, Dzamba M, et al. Evaluation of a sensitive blood test for the detection of colorectal advanced adenomas in a
prospective cohort using a multiomics approach. JCO 2021;39:43-43. DOI
43. Ulz P, Perakis S, Zhou Q, et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and
early detection. Nat Commun 2019;10:4666. DOI PubMed PMC
44. Putcha G, Gutierrez A, Skates S. Multicancer screening: one size does not fit all. JCO Precis Oncol 2021;5:574-6. DOI
45. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically meaningful use of blood tumor markers in oncology. Biomed Res Int
2016;2016:9795269. DOI PubMed PMC
46. McKeegan EM, Ansell PJ, Davis G, et al. Plasma biomarker signature associated with improved survival in advanced non-small cell
lung cancer patients on linifanib. Lung Cancer 2015;90:296-301. DOI PubMed
47. Rifai N. Tietz textbook of clinical chemistry and molecular diagnostics, 6th ed. St. Louis, MO: Saunders, 2017; Available from:
https://www.us.elsevierhealth.com/tietz-textbook-of-clinical-chemistry-and-molecular-diagnostics-9780323359214.html [Last
accessed on 29 June 2022].
48. Lamb YN, Dhillon S. Epi proColon((R)) 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther 2017;21:225-32.
DOI PubMed
49. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med
2014;370:1287-97. DOI